Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 11, 1999, Pages 2629-2634

  Nascimbeni, Michelina ^a   Lamotte, Claire ^a   Peytavin, Gilles ^a   Farinotti, Robert ^a   Clavel, François ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; TISSUE CULTURE; VIRION;

EID: 0032755474     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.11.2629     Document Type: Article

References (30)

1. Adachi, A., H. E. Gendelmann, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Autran, B., G. Carcelain, T. S. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlama, P. Debre, and J. Leibowitch. 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112-116.
3. Barry, M., S. Gibbons, D. Back, and F. Mulcahy. 1997. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin. Pharmacokinet. 32:194-209.
4. Bilello, J. A., P. A. Bilello, K. Stellrecht, J. Leonard, D. W. Norbeck, D. J. Kempf, T. Robins, and G. L. Drusano. 1996. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemotner. 40:1491-1497.
5. Bundtzen, R. W., A. U. Gerber, D. L. Cohn, and W. A. Craig. 1981. Postantibiotic suppression of bacterial growth. Rev. Infect. Dis. 3:28-37.
6. Carpenter, C. C., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1998. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 280:78-86.
7. Charneau, P., G. Mirambeau, P. Roux, S. Paulous, H. Buc, and F. Clavel. 1994. HIV-1 reverse transcription: a termination step at the center of the genome. J. Mol. Biol. 241:651-662.
8. Coffin, J. M. 1991. Retroviridae and their replication, p. 645-708. In B. Fields (ed.), Virology, 2nd ed. Raven Press, New York, N.Y.
9. Deeks, S. G., M. Smith, M. Holodniy, and J. O. Kahn. 1997. HIV-1 protease inhibitors: a review for clinicians. JAMA 277:145-153.
10. Denissen, J. F., B. A. Grabowski, M. K. Johnson, A. M. Buko, D. J. Kempf, S. B. Thomas, and B. W. Surber. 1997. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab. Dispos. 25:489-501.
11. Dorsey, B. D., R. B. Levin, S. L. McDaniel, J. P. Vacca, J. P. Guare, P. L. Darke, J. A. Zugay, E. A. Emini, W. A. Schleif, and J. C. Quintero. 1994. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37:3443-3451.
12. Dreyer, G. B., B. W. Metcalf, T. A. Tomaszek, Jr., T. J. Carr, A. C. D. Chandler, L. Hyland, S. A. Fakhoury, V. W. Magaard, M. L. Moore, J. E. Strickler, et al. 1989. Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proc. Natl. Acad. Sci. USA 86:9752-9756.
13. Erickson, J., D. Neidhart, J. VanDrie, D. Kempf, X. Wang, D. Norbeck, J. Plattner, J. Rittenhouse, M. Turon, N. Wideburg, W. Kohlbrenner, R. Simmer, R. Helfrick, D. Paul, and M. Knigge. 1990. Design, activity, and 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 249:527-533.
14. Eustice, D., P. Feldman, A. Colberg-Poley, R. Buckery, and R. Neubauer. 1991. A sensitive method for the detection of β-galactosidase in transfected mammalian cells. BioTechniques 11:739-743.
15. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
16. Havlir, D. V., and J. M. Lange. 1998. New antiretrovirals and new combinations. AIDS 12:S165-S174.
17. Hoetelmans, R. M., P. L. Meenhorst, J. W. Mulder, D. M. Burger, C. H. Koks, and J. H. Beijnen. 1997. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm. World Sci. 19:159-175.
18. Jacobsen, H., L. Ahlborn-Laake, R. Gugel, and J. Mous. 1992. Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease. J. Virol. 66:5087-5091.
19. Kageyama, S., D. T. Hoekzema, Y. Murakawa, E. Kojima, T. Shirasaka, D. J. Kempf, D. W. Norbeck, J. Erickson, and H. Mitsuya. 1994. A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro. AIDS Res. Hum. Retroviruses 10:735-743.
20. Kaplan, A. H., M. Manchester, T. Smith, Y. L. Yang, and R. Swanstrom. 1996. Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication. J. Virol. 70: 5840-5844.
21. Kempf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X. P. Kong, and D. W. Norbeck. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
22. Markowitz, M., M. Conant, A. Hurley, R. Schluger, M. Duran, J. Peterkin, S. Chapman, A. Patick, A. Hendricks, G. J. Yuen, W. Hoskins, N. Clendeninn, and D. D. Ho. 1998. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J. Infect. Dis. 177:1533-1540.
23. Marsh, K. C., E. Eiden, and E. McDonald. 1997. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J. Chromatogr. B 704:307-313.
24. Merry, C., M. G. Barry, F. Mulcahy, M. Ryan, J. Heavey, J. F. Tjia, S. E. Gibbons, A. M. Breckenridge, and D. J. Back. 1997. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11:F29-F33.
25. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H. M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
26. Moyle, G. J., M. Youle, C. Higgs, J. Monaghan, W. Prince, S. Chapman, N. Clendeninn, and M. R. Nelson. 1998. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J. Clin. Pharmacol. 38:736-743.
27. Patick, A., H. Mo, M. Markowitz, K. Appelt, B. Wu, L. Musick, V. Kalish, S. Kaldor, S. Reich, D. Ho, and S. Webber. 1996. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40:292-297.
28. Spivey, J. M. 1992. The postantibiotic effect. Clin. Pharm. 11:865-875.
29. Woolf, E., T. Au, H. Haddix, and B. Matuszewski. 1995. Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching. J. Chromatogr. A 692:45-52.
30. Zennou, V., F. Mammano, S. Paulous, D. Mathez, and F. Clavel. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:3300-3306.